Issue 29, 2024

Synthesis and immunological evaluation of TLR1/2 ligand-conjugated RBDs as self-adjuvanting vaccine candidates against SARS-CoV-2

Abstract

We synthesized and evaluated Pam3CSK4-conjugated receptor binding domain (RBD)/deglycosylated RBD as potential anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates. Our investigation revealed the critical importance of limiting the number of introduced Pam3CSK4 molecules to the RBD in order to preserve its antigenicity. We also confirmed the harmonious integration of the adjuvant-conjugation strategy with the glycan-shield removal strategy.

Graphical abstract: Synthesis and immunological evaluation of TLR1/2 ligand-conjugated RBDs as self-adjuvanting vaccine candidates against SARS-CoV-2

Supplementary files

Article information

Article type
Communication
Submitted
30 Jan 2024
Accepted
08 Mar 2024
First published
15 Mar 2024
This article is Open Access
Creative Commons BY license

Chem. Commun., 2024,60, 3946-3949

Synthesis and immunological evaluation of TLR1/2 ligand-conjugated RBDs as self-adjuvanting vaccine candidates against SARS-CoV-2

Y. Manabe, B. Gárate-Reyes, K. Ito, R. Hurtado-Guerrero, K. Kabayama and K. Fukase, Chem. Commun., 2024, 60, 3946 DOI: 10.1039/D4CC00462K

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements